Jpmorgan Chase & CO Sensei Biotherapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SNSE
# of Institutions
22Shares Held
2.23MCall Options Held
0Put Options Held
0-
Ikarian Capital, LLC Dallas, TX650KShares$292,5000.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA619KShares$278,4400.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny216KShares$97,0070.0% of portfolio
-
Boothbay Fund Management, LLC New York, NY173KShares$77,7750.0% of portfolio
-
Geode Capital Management, LLC Boston, MA163KShares$73,4120.0% of portfolio
About Sensei Biotherapeutics, Inc.
- Ticker SNSE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,720,300
- Market Cap $13.8M
- Description
- Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...